Kyverna Therapeutics Inc. (NASDAQ: KYTX) reported interim results from its phase 2 trial of KYV-101 for generalized myasthenia gravis, with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE